Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964452 | 0.76 | POLB (0.37) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18026348 | 0.71 | ALDH1A1 (0.47) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18860307 | 0.70 | ALDH1A1 (0.44) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL17614835 | 0.70 | POLB (0.41) | POLBHDAC2PIK3CD | |
| SCHEMBL18594653 | 0.69 | POLB (0.46) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL13160839 | 0.69 | POLB (0.40) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL23869689 | 0.69 | ALDH1A1 (0.39) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL20214934 | 0.67 | HPGD (0.47) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8013070 | 0.66 | MAPT (0.46) | POLBHDAC2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5318521 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | POLB 4236/4885HDAC2 804/4885ALDH1A1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.